Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
A total dose of 40.05Gy in 15 fractions was delivered to the tumor bed for each eligible breast cancer patients. The endpoints including loco-regional recurrence, cosmetic outcomes, and toxicities, were evaluated after treatment.
Age
50–85
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female
Age≥ 50 years
Treated with breast conversing surgery and sentinel lymph node biopsy or axillary lymph node dissection
Negative surgical margins
Pathologically confirmed invasive breast cancer
A pathological T1N0M0 tumor -IHC: ER+/PR+/HER2-
Tumor bed is labeled with Titanium clips
Received adjuvant hormonal treatment
No adjuvant chemotherapy
ECOG:0-1
Written informed consent.
You may not be if
Age\<50 years
KPS\<70
Treated with neoadjuvant chemotherapy
Treated or being treated with chemotherapy
With severe comorbidity
Previous breast cancer or other malignant tumor history
Previous radiotherapy for breast or thorax
Medical contraindication for radiotherapy
Pregnant or nursing
Clareo Health | Hypofractionated PBI After BCS for Low-risk Breast Cancer Patients
